MedTrace Logo

GS3-007a Oral Solution in Healthy Subjects

NCT05611281 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2023-04-11

No results posted yet for this study

Summary

To evaluate the safety and tolerability of GS3-007A in single, multiple, and single oral administration after high-fat meals in Chinese healthy adults.

Conditions

  • Healthy Subject

Interventions

DRUG

GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication

The dosage was calculated according to body weight and dose group once a day according to the assigned group.

Sponsors & Collaborators

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-22
Primary Completion
2023-04-01
Completion
2023-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05611281 on ClinicalTrials.gov